Skip to main content

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • For Subscribers
    • For Advertisers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • For Subscribers
    • For Advertisers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleArticle

Differential Effect of Histamine 3 Receptor-Active Agents on Brain, but not Peritoneal, Mast Cell Activation ,

Jacek J. Rozniecki, Richard Letourneau, Miltiades Sugiultzoglu, Constantinos Spanos, Jonathan Gorbach and Theoharis C. Theoharides
Journal of Pharmacology and Experimental Therapeutics September 1999, 290 (3) 1427-1435;
Jacek J. Rozniecki
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard Letourneau
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Miltiades Sugiultzoglu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Constantinos Spanos
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jonathan Gorbach
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Theoharis C. Theoharides
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The activation of presynaptic histamine 3 (H3) receptors inhibits the release of histamine and other neurotransmitters from central nervous system neurons. Rat brain mast cells (MCs) release histamine and 5-hydroxytryptamine (5-HT) in response to neuropeptides and neurotransmitters secreted from adjacent neurons. Dura MCs also degranulate in response to antidromic trigeminal nerve stimulation and with acute psychological stress. Such findings have implicated brain MCs in certain neuroinflammatory disorders, such as migraines. We investigated the ultrastructural appearance of control and stimulated thalamic/hypothalamic (brain) MCs before and after treatment with the H3 receptor agonistNα-methylhistamine (Nα-mH) and the H3 receptor antagonist thioperamide (Th). Ultrastructural investigation of brain MCs stimulated with compound 48/80 revealed extensive intragranular changes that paralleled 5-HT secretion but without degranulation by exocytosis typical of connective tissue MCs. Nα-mH significantly reduced these morphological changes, as well as 5-HT release from brain MCs and neurons stimulated with KCl; conversely, Th augmented both histamine and 5-HT release from brain neurons and MCs. Neither Nα-mH nor Th had any effect on peritoneal MCs. Simultaneous addition of both drugs largely antagonized each other’s effects on brain MC activation and 5-HT secretion. Ultrastructural observations and lack of lactic dehydrogenase release in the perfusate excluded any cytotoxic effect. The ability of H3 agonists to inhibit brain MC activation, as well as secretion of 5-HT from both brain MCs and neurons, may be useful in the management of migraines.

Footnotes

  • Send reprint requests to: T. C. Theoharides, Ph.D., M.D., Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine, 136 Harrison Ave., Boston, MA 02111. E-mail: ttheoharides{at}infonet.tufts.edu

  • ↵1 This work was supported by a grant from Kos Pharmaceuticals (Miami, FL).

  • ↵2 The possible therapeutic use of H3 agonists in the treatment of migraines is covered by U.S. Patent 5,855,884 awarded to T.C.T.

  • ↵3 Present address: Department of Neurology, Medical Academy, Lodz 90153, Poland.

  • ↵4 Present address: Department of Neurosurgery, Cornell Medical College, Cornell, NY 10021.

  • ↵5 Present address: Department of Surgery, New England Medical Center, Boston, MA 02111.

  • ↵6 Present address: Department of Emergency Medicine, Langley Air Force Base, Hampton, VA 23665.

  • Abbreviations:
    CNS
    central nervous system
    C48/80
    compound 48/80
    CTMC
    connective tissue mast cell
    H3
    histamine 3
    5-HT
    5-hydroxytryptamine (serotonin)
    IMI
    imipramine
    KRB
    Krebs-Ringer bicarbonate buffer
    LDH
    lactic dehydrogenase
    MC
    mast cell
    mH
    methylhistamine
    MS
    multiple sclerosis
    Nα-mH
    Nα-methylhistamine
    RIA
    radioimmunoassay
    Th
    thioperamide
    TNF
    tumor necrosis factor
    • Received November 3, 1998.
    • Accepted April 29, 1999.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

Log in using your username and password

Forgot your user name or password?

Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$35.00

Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.

PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 290 (3)
Journal of Pharmacology and Experimental Therapeutics
Vol. 290, Issue 3
1 Sep 1999
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Differential Effect of Histamine 3 Receptor-Active Agents on Brain, but not Peritoneal, Mast Cell Activation ,
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
Citation Tools
Research ArticleArticle

Differential Effect of Histamine 3 Receptor-Active Agents on Brain, but not Peritoneal, Mast Cell Activation ,

Jacek J. Rozniecki, Richard Letourneau, Miltiades Sugiultzoglu, Constantinos Spanos, Jonathan Gorbach and Theoharis C. Theoharides
Journal of Pharmacology and Experimental Therapeutics September 1, 1999, 290 (3) 1427-1435;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Differential Effect of Histamine 3 Receptor-Active Agents on Brain, but not Peritoneal, Mast Cell Activation ,

Jacek J. Rozniecki, Richard Letourneau, Miltiades Sugiultzoglu, Constantinos Spanos, Jonathan Gorbach and Theoharis C. Theoharides
Journal of Pharmacology and Experimental Therapeutics September 1, 1999, 290 (3) 1427-1435;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Experimental Procedures
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Streptococcus pneumoniae Pneumonia in Mice: Optimal Amoxicillin Dosing Predicted from a Pharmacokinetic-Pharmacodynamic Model
  • Tissue Selectivity of Antidiabetic Agent Nateglinide: Study on Cardiovascular and β-Cell KATP Channels
  • Distribution in Rat Brain of Binding Sites of Kaliotoxin, a Blocker of Kv1.1 and Kv1.3 α-Subunits
Show more Article

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2019 by the American Society for Pharmacology and Experimental Therapeutics